NICE 'too quick' to block drugs

NICE too readily blocks access to new drugs and lacks research expertise needed to support value-based pricing, health economists have argued.

A report by the University of York’s Centre for Health Economics (CHE) said NICE underuses the option of backing a drug’s use ‘only in research’.

NICE currently has at least four options when assessing new technologies: reject, approve, approve only in research and approve with research. But NICE rarely recommends approval only in research or with research, the CHE said.

When value-based pricing is introduced, restricted approvals will be important as they broaden options for negotiation alongside cost-effectiveness assessments, the report argued.

In addition, NICE does not currently have the expertise to determine what types of research are needed to address questions about the cost-effectiveness of drugs, the CHE said.

The University of York team argue that valuable information on cost-effectiveness may not be unavailable when a drug is first launched.

Their paper sets out ways in which the benefits of waiting for new research findings can be balanced against the harm caused by delaying access to a new medicine.

The research was commissioned by NICE and funded by the NHS’s National Institute for Health Research and the Medical Research Council.

Professor Carole Longson, director of NICE’s centre for health technology evaluation, said NICE would be considering the findings carefully. ‘We are continually looking at ways we can improve our ap-praisal processes,’ she said

‘We will, of course, need to wait until the Government has finalised its ideas for how VBP will work before we can confirm our own plans, but we feel our current processes are well-placed for the transition to value-based pricing.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

RCGP urges GPs to collaborate with pharmacies on flu jabs this year

RCGP urges GPs to collaborate with pharmacies on flu jabs this year

The RCGP and the Royal Pharmaceutical Society have called on GP practices and community...

GP appointments rising fast as COVID-19 cases 'near 10,000 a day'

GP appointments rising fast as COVID-19 cases 'near 10,000 a day'

GP appointments have risen rapidly in recent weeks as schools returned, according...

COVID-19 impact on medical schools risks 'serious damage' to future NHS workforce

COVID-19 impact on medical schools risks 'serious damage' to future NHS workforce

Medical training and the future NHS workforce could be seriously damaged by the financial...

GPonline's news editor wins medical journalism award

GPonline's news editor wins medical journalism award

GPonline news editor Nick Bostock has won News Story of the Year (specialist media)...

How GPs can support patients with 'long COVID'

How GPs can support patients with 'long COVID'

GPs must be ready to support patients with physical, psychological and social problems...

BMA demands 'rule of six' overhaul to prevent further lockdowns

BMA demands 'rule of six' overhaul to prevent further lockdowns

The government must scrap its high-risk ‘rule of six’ and introduce more stringent...